# US 2012/0251570 A1 · Method, kit, plasmid and composition for inducing an immune response to dengue virus, on the basis of dna and chimeric virus vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251570 A1
- Document ID: US20120251570A1
- Status: Published application
- Kind: A1
- Application number: 13/499,697
- Filed: 2010-08-01
- Published: 2012-10-04
- Earliest claimed: 2009-10-01
- Assignees: FundaçãO Oswaldo Cruz
- Inventors: Ada Maria de Barcelos Alves; Adriana de Souza Azevedo; Ricardo Galler; Marcos da Silva Freire
- Web page: https://patentgrep.com/patent/US20120251570A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/53: {DNA (RNA) vaccination}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a method for inducing an immune response to the dengue virus, on the basis of DNA and 17D chimeric virus vaccines in combined or co-administered immunisation. The scope of the present invention also includes DNA vaccines against the four serotypes of the dengue virus, produced by forming, from each viral serotype of the dengue virus (DENV1-4), various recombinant plasmids that contain the gene that codes for the E protein, or that contain only the sequence that corresponds to the domain III of this protein. The invention also provides a vaccine composition consisting of (a) DNA vaccines against the four serotypes of the dengue virus; (b) chimeric viruses comprising the modified yellow fever vaccination virus 17D; and (c) a pharmaceutically acceptable carrier, all of which are covered by the scope of the invention.

## Claims

### Claim 1

A method to induce an immune response against dengue virus comprising administration to a patient of DNA vaccines and 17D chimeric viruses.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the administration is conducted in combination immunizations, in a prime (DNA vaccines) and boost (chimeric viruses) system or simultaneous co-administration of the (DNA and chimeric viruses vaccines in a same formulation).

### Claim 3

A vaccine composition against dengue virus comprising:
(a) DNA vaccines against four dengue virus serotypes from a construction of different recombinant plasmids containing genes codifying proteins E from each of the dengue virus serotypes, or only the sequences corresponding to domains III of said proteins, all of the foregoing fused to a sequence which codifies a signal peptide of human tissue plasminogen activator (t-PA);
(b) chimeric viruses comprising a yellow fever vaccine virus 17D modified by infectious clone attainment technology, with a replacement of sequences codifying the yellow fever prM and E proteins by sequences codifying the prM and E proteins of dengue virus from different serotypes; and
(c) a pharmaceutically acceptable vehicle.

### Claim 4 (depends on 3)

The composition according to claim 3, wherein the DNA vaccines comprise:
plasmid pE1 constructed by inserting a sequence codifying 80% of a protein from the dengue virus viral envelope (E), without a C-terminal portion of dengue virus protein E.

### Claim 5 (depends on 3)

The composition according to claim 3, wherein the DNA vaccines comprise:
a plasmid pE2 constructed with an insertion of a sequence codifying domain III of dengue virus protein E, contained between nucleotides 1822 and 2125 of dengue virus complete genome.

### Claim 6

A kit comprising:
(a) DNA vaccines against four dengue virus serotypes from a construction of different recombinant plasmids containing genes codifying proteins E from each of the dengue virus serotypes, or only sequences corresponding to domains III of said proteins, all of the foregoing fused to a sequence which codifies a signal peptide of human tissue plasminogen activator (t-PA); and
(b) chimeric viruses comprising a yellow fever vaccine virus 17D modified by infectious clone attainment technology, with a replacement of sequences codifying yellow fever prM and E proteins by sequences codifying the prM and E proteins of dengue virus from different serotypes.

### Claim 7

A recombinant plasmid containing a protein E gene and from each dengue virus serotype fused to a sequence codifying a t-PA signal peptide, said plasmid being constructed by inserting a sequence codifying 80% of the protein from the dengue virus viral envelope (E) without a C-terminal portion of protein E, where such sequence is amplified using sense and antisense oligonucleotides, identified as SEQ ID NO:3 and SEQ ID NO:4, and subsequently conducted cloning of a sequence in plasmid pcTPA between restriction enzymes EcoRV e XbaI1 enzymes sites in a same open reading frame of the sequence codifying the signal peptide t-PA, generating the recombinant plasmid.

### Claim 8 (depends on 7)

The plasmid according to claim 7, wherein the sequence codifying 80% of the dengue virus viral envelope protein (E) is contained between nucleotides 937 and 213125 of DENV2 complete genome, New Guinea C(NGC) strain (Genebank: M29095).

### Claim 9

A recombinant plasmid containing a protein E gene and from each dengue virus serotype fused to a sequence codifying a t-PA signal peptide, said plasmid being constructed by inserting a sequence codifying domain III of dengue virus protein E, where such sequence is amplified using sense and antisense oligonucleotides, identified as SEQ ID NO:5 and SEQ ID NO:4, between restriction enzymes EcoRV e XbaI sites and subsequently cloning of the sequence is performed between the restriction enzymes EcoRV e Xba1 sites, in a same open reading frame of the sequence codifying the signal peptide t-PA, generating the recombinant plasmid.

### Claim 10 (depends on 9)

The plasmid according to claim 9, wherein the sequence codifying domain II of dengue virus protein E is contained between nucleotides 1822 and 213125 of DENV2 complete genome, NGC strain (Genebank: M29095).
